Work

Supplementary Information from The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity

Year: 2023

Type: supplementary-materials

Abstract: This file contains: Supplementary Methods for pharmacodynamic biomarker analyses, clinicaltrials.gov searches, and molecular correlation analyses; Supplementary Figures S1 (overview of the NCI-ALMANAC web resource), S2 (apoptotic biomarker response to bortezomib-clofarabine), and S3 (associations between ABC transporter activity and nilotinib-paclitaxel combination activity); and Supplementary Tables S1 (FDA-approved agents used in the NCI-ALMANAC screen), S2 (tumor doubling time analysis of xenograft experiments with clinically tested NCI-ALMANAC-derived combinations), S3 (in vitro, in vivo, and clinical activity of NCI-ALMANAC-derived combinations), and S4 (tumor doubling time analysis of xenograft experiments with novel NCI-ALMANAC-derived combinations).

DOI: 10.1158/0008-5472.22413824

Authors: Susan L. Holbeck, Richard Camalier, James A. Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W. Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, Jerry M. Collins, James H. Doroshow

Language: English

Topic: Computational Drug Discovery Methods

Subfield: Computational Theory and Mathematics

Field: Computer Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362335730

Cites:

Cited by:

Related to: 10